AngioDynamics, Inc. (NASDAQ:ANGO) Stock Has Average Target Price of $19.00

AngioDynamics, Inc. (NASDAQ:ANGO) has been assigned a consensus recommendation of “Moderate Buy” from the five ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $19.00.

A number of equities analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Thursday, October 15th. Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. Wall Street Zen cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 target price on shares of AngioDynamics in a report on Friday, October 9th. Finally, HC Wainwright decreased their price target on AngioDynamics from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, October 13th.

AngioDynamics Stock Performance

Shares of NASDAQ:ANGO opened at $11.89 on Thursday. AngioDynamics has a 52 week low of $9.39 and a 52 week high of $16.29. The company’s fifty day moving average is $14.68 and its 200-day moving average is $13.14. The company has a market capitalization of $500.02 million, a PE ratio of -15.24 and a beta of 0.30.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.07. The business had revenue of $80.92 million for the quarter, compared to analyst estimates of $80.51 million. AngioDynamics had a negative net margin of 10.12% and a negative return on equity of 4.49%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, analysts forecast that AngioDynamics will post -0.26 EPS for the current year.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of the business’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the transaction, the senior vice president owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 6.00% of the company’s stock.

Institutional Trading of AngioDynamics

Several large investors have recently made changes to their positions in ANGO. Integrated Wealth Concepts LLC acquired a new stake in AngioDynamics in the 2nd quarter valued at about $38,000. Corient Private Wealth LP bought a new position in shares of AngioDynamics in the second quarter worth about $134,000. Public Employees Retirement System of Ohio acquired a new position in shares of AngioDynamics during the second quarter worth approximately $64,000. Bank of America Corp DE bought a new stake in shares of AngioDynamics during the second quarter valued at approximately $4,490,000. Finally, Gallagher Fiduciary Advisors LLC acquired a new stake in shares of AngioDynamics in the second quarter valued at approximately $589,000. Institutional investors own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.